SELECT PUBLICATIONS
Gamelin L et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium
infusions: A retrospective study of 161 patients receiving oxaliplatin combined
with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res
2004;10(12 Pt 1):4055-61. Abstract
Grothey A et al. Association between exposure to bevacizumab (BV) beyond first
progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal
cancer (mCRC): Results from a large observational study (BRiTE). Proc ASCO
2007;Abstract 4036.
Hochster HS et al. Use of calcium and magnesium salts to reduce oxaliplatin-related
neurotoxicity. J Clin Oncol 2007;[Epub ahead of print]. No abstract available
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Eng J Med 2004;350(23):2335-42. Abstract
Maindrault-Goebel F et al. Final results of OPTIMOX2, a large randomized phase II
study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX
in patients with metastatic colorectal cancer (MRC): A GERCOR study. Proc ASCO
2007;Abstract 4013.
Meyers MO et al. Ratio of metastatic to examined lymph nodes is a powerful predictor
of overall survival in rectal cancer: An analysis of Intergroup 0114. Proc ASCO
2007;Abstract 4006.
Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory
colorectal cancer. Gastrointestinal Cancers Symposium 2005;Abstract 169b.
Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with
oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR
study. J Clin Oncol 2006;24(3):394-400. Abstract
Wang WS et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007;12(3):312-9. Abstract
